patients with degen- erative neurological symptoms, a diagnosis of adrenoleukodystro- phy should be excluded.

Reading File

Finding Sources

Searching PubMed

adrenoleukodystrophy diagnosis neurological symptoms

Reading File

Searching Images

adrenoleukodystrophy MRI brain white matter demyelination

This composite diagnostic image presents axial brain MRI scans from a patient with adrenomyeloneuropathy (AMN) transitioning to cerebral adrenoleukodystrophy (cALD). Panels A (T2-weighted) and C (FLAIR) demonstrate progressive white matter disease. Initially, hyperintense signals are localized in the splenium of the corpus callosum and periventricular parieto-occipital white matter. Follow-up imaging in Panel C shows significant spatial extension of these lesions, appearing more confluent and diffuse. Panels B and D provide T1-weighted sequences with gadolinium contrast. While the initial scan (B) shows no pathological enhancement, the follow-up scan (D) reveals faint rim enhancement at the leading edge of the demyelinating lesion. This contrast enhancement is a critical clinical marker of active neuroinflammation and blood-brain barrier disruption. The series illustrates the radiologic hallmarks of X-linked adrenoleukodystrophy progression, including the characteristic posterior-to-anterior spread of demyelination and the transition to an active inflammatory stage.

This diagnostic image set consists of two axial brain MRI scans from a 27-year-old male with adolescent cerebral-type adrenoleukodystrophy (ALD). Image (A) is a Fluid-Attenuated Inversion Recovery (FLAIR) sequence showing symmetric, diffuse, high-intensity signals in the posterior deep white matter, specifically involving the parieto-occipital lobes. This represents demyelination or vasogenic edema. Image (B) is a post-gadolinium contrast-enhanced T1-weighted sequence of the same region. It highlights linear border enhancement (indicated by yellow arrowheads) at the leading edges or anterior periphery of the white matter lesions. This peripheral enhancement is characteristic of active inflammatory demyelination and breakdown of the blood-brain barrier. These findings are clinically significant for monitoring disease progression in X-linked adrenoleukodystrophy, illustrating the classic radiographic 'zonal' pattern of the condition.

This diagnostic imaging panel consists of axial brain MRI sequences (A-E) illustrating characteristic white matter lesions associated with X-linked adrenoleukodystrophy (X-ALD). The panel includes T1-weighted (A, B), Fluid-Attenuated Inversion Recovery (FLAIR) (C), and T2-weighted (D, E) sequences. There is prominent bilateral, symmetrical signal abnormality involving the periventricular white matter, primarily within the posterior regions including the temporal, parietal, and occipital lobes. On T1-weighted images, these areas appear as regions of decreased signal intensity (hypointense). In contrast, the FLAIR and T2-weighted sequences demonstrate significant hyperintensity in the same distribution, indicating demyelination and abnormal fluid accumulation. Lesions are also visible within the brainstem. The distribution follows a characteristic 'butterfly' pattern in the posterior cerebrum, which is a classic radiographic sign for pediatric cerebral X-ALD. This imaging is used for medical education to demonstrate neurodegenerative metabolic disorders and the radiographic evolution of leukodystrophies.

Reading File

Loading Image

Here is a thorough overview of Adrenoleukodystrophy (ALD) and why it must be excluded in patients with degenerative neurological symptoms.

Adrenoleukodystrophy (ALD)

Overview and Genetics

ALD is an X-linked recessive peroxisomal disorder with an incidence of approximately 1 in 20,000–25,000 male births. It was originally described under the rubric of "Schilder disease" but is now recognized as an independent metabolic encephalopathy. The fundamental defect is a mutation in the ABCD1 gene (located at chromosome Xq28), which encodes a peroxisomal membrane transporter (ALDP) - a member of the ATP-binding cassette (ABC) transporter family. This protein normally shuttles activated acyl-CoA derivatives into peroxisomes for beta-oxidation. When it fails, very long-chain fatty acids (VLCFAs) - particularly C24, C25, and C26 - accumulate in the brain, adrenal cortex, testes, and liver. - Adams and Victor's Principles of Neurology, 12th Ed.

Clinical Phenotypes

Because of incomplete penetrance and variable VLCFA accumulation, ALD presents as several distinct clinical subtypes from the same underlying mutation (Goldman-Cecil Medicine):

Phenotype	Population	Onset	Key Features	% of Cases
Childhood cerebral ALD	Males	4-11 years	Cognitive decline, behavioral change, cortical blindness, seizures, progressive to decerebration	~45-50%
Adolescent/adult cerebral	Males	Teens-adult	Similar to childhood form, slower progression	~5-8%
Adrenomyeloneuropathy (AMN)	Males	3rd-5th decade	Slowly progressive spastic paraparesis, peripheral neuropathy, sphincter disturbances, hypogonadism, variable adrenal insufficiency	~25%
Female carrier myelopathy	Heterozygous females	3rd-4th decade	Mild-moderate spastic paraparesis, gait ataxia, urinary incontinence; can mimic MS	~10-20%
Isolated Addison disease	Males	Variable	No neurologic involvement; only adrenal insufficiency	~10%

The classic childhood form starts with episodic vomiting, decline in school performance, personality change, and gait disturbance. Skin bronzing (hyperpigmentation from adrenal failure) may appear later. The late stages feature bilateral hemiplegia, pseudobulbar paralysis, blindness, and deafness. - Adams and Victor's Principles of Neurology, 12th Ed.

Why ALD Must Be Excluded in Degenerative Neurological Presentations

Several features make ALD a critical "must-exclude" diagnosis:

Mimics common conditions: AMN in adults closely mimics multiple sclerosis, hereditary spastic paraplegia, or other spinocerebellar degenerations. Up to 20% of female carriers have white matter changes on MRI, making MS the primary differential. Rare presentations include olivopontocerebellar atrophy and adult-onset spinocerebellar ataxia patterns.
Adrenal involvement may be subtle: Overt Addison disease may not be apparent, particularly in female carriers or in adult AMN. The neurology can precede recognizable adrenal signs.
The diagnosis is biochemically confirmable: Plasma VLCFA levels (C26 absolute level; C26:C22 ratio; C24:C22 ratio) are reliably elevated. Combined plasma and fibroblast testing detects ~93% of female carriers.
Treatment exists: Adrenal replacement therapy prolongs life. Early hematopoietic stem cell transplantation or gene therapy (lentiviral ABCD1 transduction of autologous CD34+ cells) can stabilize or prevent progression if started early. Missing the diagnosis delays these interventions.

MRI Findings

The classic MRI pattern in cerebral ALD shows posterior periventricular white matter T2/FLAIR hyperintensity starting in the splenium of the corpus callosum and spreading anteriorly. Active inflammatory lesions show rim enhancement with gadolinium contrast at the leading edge (blood-brain barrier disruption).

Figure 36-8 from Adams and Victor's Principles of Neurology (8-year-old boy):

Axial T2 MRI of ALD showing posterior periventricular white matter hyperintensity crossing the splenium of the corpus callosum

The butterfly/posterior pattern of demyelination in ALD:

MRI panel showing classic butterfly distribution of posterior white matter hyperintensity in X-ALD on T1, FLAIR, and T2 sequences

In AMN transitioning to cerebral ALD:

Composite MRI panel showing AMN to cALD transition with T2/FLAIR periventricular lesions and rim enhancement on gadolinium-T1

Pathology

Massive, often asymmetric demyelination occurs in the cerebrum, brainstem, optic nerves, and sometimes spinal cord. Myelin degradation products are visible in macrophages (sudanophilic demyelination). The adrenal cortex is atrophic with abnormal lipid-laden cells. Electron microscopy shows characteristic lamellar cytoplasmic inclusions in macrophages, adrenal cells, and Leydig cells of the testes - a hallmark of VLCFA accumulation. - Adams and Victor's Principles of Neurology, 12th Ed.

Diagnostic Workup

Plasma VLCFAs: Elevated C26, C26:C22, and C24:C22 ratios - the primary biochemical marker
ABCD1 gene sequencing: Confirms the diagnosis
Brain MRI: Posterior periventricular hyperintensity on T2/FLAIR; gadolinium enhancement at active lesion margins
Adrenal function: Low serum sodium, elevated potassium, low cortisol, absent rise in 17-hydroxyketosteroids post-ACTH stimulation
Nerve biopsy (in AMN): Loss of myelinated and unmyelinated fibers with lamellar inclusions in Schwann cell cytoplasm
CSF: May show elevated protein

Treatment

Modality	Indication	Notes
Adrenal replacement therapy	Adrenal insufficiency	Prolongs life; may produce partial neurologic remission
Lorenzo's oil (erucic + oleic acids)	Normalizes plasma VLCFAs	Large open-label trials failed to show neurologic efficacy
Allogeneic bone marrow transplantation	Early cerebral ALD	Stabilizes disease; reverses some MRI changes if done early
Gene therapy (lentiviral ABCD1 into CD34+ cells)	Early disease, pre-symptomatic	Prevents symptom emergence; most promising if instituted early

Harrison's Principles of Internal Medicine, 22nd Ed.; Adams and Victor's Principles of Neurology, 12th Ed.

Clinical Bottom Line: Any patient - male or female - presenting with progressive spastic paraparesis, cognitive decline, demyelinating white matter disease on MRI, or unexplained adrenal insufficiency should have plasma VLCFAs measured to exclude ALD/AMN. The diagnosis is biochemically straightforward, the genetic cause is confirmed by ABCD1 sequencing, and missing it forfeits the window for disease-modifying therapy.

This is a shared conversation. Sign in to Orris to start your own chat.